Tyck till om SwePub Sök här!
WFRF:(Lip Gregory Y H)
Sökning: WFRF:(Lip Gregory Y H) > Olsson Bertil > Persson Anders L. > Oral direct thrombi...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- Lip, Gregory Y. H. (författare)
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists
- Artikel/kapitelEngelska2009
Förlag, utgivningsår, omfång ...
- 2009-08-18
- Oxford University Press (OUP),2009
Nummerbeteckningar
- LIBRIS-ID:oai:lup.lub.lu.se:24dc0397-a991-4e3f-a25a-0c96c698f745
- https://lup.lub.lu.se/record/1533572URI
- https://doi.org/10.1093/eurheartj/ehp318DOI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- Aims Oral anticoagulation with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) is effective but has significant limitations. AZD0837, a new oral anticoagulant, is a prodrug converted to a selective and reversible direct thrombin inhibitor (AR-H067637). We report from a Phase II randomized, dose-guiding study (NCT00684307) to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of extended-release AZD0837 in patients with AF. Methods and results Atrial fibrillation patients (n = 955) with >= 1 additional risk factor for stroke were randomized to receive AZD0837 (150, 300, or 450 mg once daily or 200 mg twice daily) or VKA (international normalized ratio 2-3, target 2.5) for 3-9 months. Approximately 30% of patients were naive to VKA treatment. Total bleeding events were similar or lower in all AZD0837 groups (5.3-14.7%, mean exposure 138-145 days) vs. VKA (14.5%, mean exposure 161 days), with fewer clinically relevant bleeding events on AZD0837 150 and 300 mg once daily. Adverse events were similar between treatment groups; with AZD0837, the most common were gastrointestinal disorders (e.g. diarrhoea, flatulence, or nausea). D-Dimer, used as a biomarker of thrombogenesis, decreased in all groups in VKA-naive subjects with treatment, whereas in VKA pre-treated patients, D-dinner levels started tow and remained low in all groups. As expected, only a few strokes or systemic embolic events occurred. In the AZD0837 groups, mean S-creatinine increased by similar to 10% from baseline and returned to baseline following treatment cessation. The frequency of serum alanine aminotransferase >= 3 x upper limit of normal was similar for AZD0837 and VKA. Conclusion AZD0837 was generally well tolerated at all doses tested. AZD0837 treatment at an exposure corresponding to the 300 mg od dose in this study provides similar suppression of thrombogenesis at a potentially lower bleeding risk compared with dose-adjusted VKA.
Ämnesord och genrebeteckningar
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kardiologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Cardiac and Cardiovascular Systems hsv//eng
- Direct thrombin inhibitor
- AZD0837
- Atrial fibrillation
- Vitamin K antagonists (VKAs)
- Stroke prevention
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Rasmussen, Lars H. (författare)
- Olsson, BertilLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)kard-bol (författare)
- Jensen, Eva C. (författare)
- Persson, Anders L. (författare)
- Eriksson, Ulf (författare)
- Wahlander, Karin F. C. (författare)
- KardiologiSektion II (creator_code:org_t)
Sammanhörande titlar
- Ingår i:European Heart Journal: Oxford University Press (OUP)30:23, s. 2897-29071522-96450195-668X
Internetlänk
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Lip, Gregory Y. ...
- Rasmussen, Lars ...
- Olsson, Bertil
- Jensen, Eva C.
- Persson, Anders ...
- Eriksson, Ulf
- visa fler...
- Wahlander, Karin ...
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kardiologi
- Artiklar i publikationen
- European Heart J ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
